Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07487454 · ClinicalTrials.gov registry record · NA
Sham-Controlled Rapid-Acting Neuromodulation for Depression
A NA study, sponsored by University of California, Davis.
- Not yet
- Registry status
- NA
- Development phase
- 264
- Enrollment target
NCT07487454: Clinical Trial NA study, sponsored by University of California, Davis.
NCT07487454 is a NA study that has not yet begun recruiting, run by University of California, Davis. The registered enrollment target is 264 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07487454, a NA study, has not yet begun recruiting, sponsored by University of California, Davis.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 264 participants
- Enrollment target
Study Summary
The goal of this study is to learn whether 5 days of accelerated intermittent theta burst stimulation (iTBS), a rapid form of transcranial magnetic stimulation (TMS), which is a non-invasive procedure that uses magnetic fields to stimulate brain activity, works to treat depression in adults. The main questions it aims to answer are: * Does accelerated iTBS reduce depressive symptoms compared to sham (placebo) stimulation? * Are there measurable brain, biological, and digitally measured emotion changes associated with treatment response? Participants will: * Be randomly assigned to receive either active iTBS or sham stimulation * Receive 10 stimulation sessions per day for 5 consecutive days (total of 50 sessions) * Complete MRI brain scans and EEG recordings before and after treatment * Provide blood and saliva samples to measure biological markers * Complete depression rating scales and questionnaires at baseline, during treatment, and at follow-up visits * Use a secure mobile app to record brief facial and vocal samples during the 5-day treatment and at follow-up visits * Return for follow-up visits at 1 week and at 1, 3, 6, and 12 months after treatment
Primary Outcome
Change in depressive symptoms (MADRS scores)
Interventions
- DEVICE Sham (No Treatment)
- DEVICE intermittent theta burst stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2026-12 |
| Est. Completion | 2028-05 |
| Phase | NA |
What is known before NCT07487454 opens enrollment
NCT07487454 is an interventional study that assigns participants to a tested intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham (No Treatment) is the first listed.
NCT07487454 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07487454 about?
NCT07487454 is a clinical study titled "Sham-Controlled Rapid-Acting Neuromodulation for Depression". The goal of this study is to learn whether 5 days of accelerated intermittent theta burst stimulation (iTBS), a rapid form of transcranial magnetic stimulation (TMS), which is a non-invasive procedure that uses magnetic fields to stimulate brain activity, works to treat depression in adults. The ma...
What is the current status of trial NCT07487454?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 264 participants. The study started on 2026-12. Estimated completion is 2028-05.
What interventions are being tested in trial NCT07487454?
The interventions under investigation include: Sham (No Treatment) (DEVICE), intermittent theta burst stimulation (DEVICE).
Who is sponsoring clinical trial NCT07487454?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07487454's enrollment target sits among peer trials
264 395th of 2000 higher than 1,605 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia